DNA three-lens brief
Evidence-based stock research on DNA. Three independent lenses — Quality, Momentum, Context — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Outperforming SPY by 24.5pp over 30 days. · Currently unprofitable on a trailing basis — no P/E multiple available.
- Outperforming SPY by 24.5pp over 30 days.
- Currently unprofitable on a trailing basis — no P/E multiple available.
- Negative free cash flow last quarterly (-$77.93M).
- Debt-to-equity of 92.7 — balance-sheet-heavy.
DNA closed at $8.45 (+1.33%) as of 2026-05-13. Market cap: $552.06M. Positives: outperforming SPY by 24.5pp over 30 days.. Concerns: currently unprofitable on a trailing basis — no P/E multiple available.; negative free cash flow last quarterly (-$77.93M).. Last quarter: Revenue $19.47M, net income -$82.59M, free cash flow -$77.93M.
Why three lenses on DNA, not one.
A single reasoning model has blind spots it doesn’t know about. We examine DNAacross Quality (fundamentals), Momentum (price action and sentiment), and Context (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/DNA" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath DNA brief"></iframe>